We're talking about steroid-refractory aGvHD and the important parameter of time - an improved product that's been available in an EAP, potential investigators becoming familiar with it and the approval of Ruxolitinib based on Reach1 whose results were truly appalling.
May I ask why you insist on pushing the narrative that SI avoided doing a "proper" when you've admitted to me you don't know whether or not KOL Dr. Susan Prockop was asked if she'd run one?
We're talking about steroid-refractory aGvHD and the important...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.000(0.00%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.03 | $1.03 | $215.3K | 209.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 190912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 31178 | 7 |
View Market Depth
| Last trade - 10.05am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
0.000 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.03 | $1.03 | $1.02 | 86118 | ||
| Last updated 10.22am 17/05/2024 ? | |||||
| MSB (ASX) Chart |